[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"end-stage-kidney-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:end-stage-kidney-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,55,81,108,129,160,182,214,244,270,298,319,346,373,399,422,445,472,497],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100639360","comparison-of-citrate-and-heparin-anticoagulation-during-postdilution-hemodiafiltration-100639360",false,"NCT07618858","Comparison of Citrate and Heparin Anticoagulation During Postdilution Hemodiafiltration","Efficiency and Biocompatibility of Postdilution Hemodiafiltration Using Different Anticoagulation Methods: A Randomized Crossover Clinical Trial","CITRA-HDF","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* End-stage kidney disease requiring maintenance postdilution hemodiafiltration\n* Stable chronic hemodialysis treatment three times weekly\n* Functional arteriovenous fistula\n\nExclusion Criteria:\n\n* Therapeutic anticoagulation therapy\n* Dual antiplatelet therapy\n* Significant coagulopathy\n* Active bleeding\n* Acute kidney injury","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized crossover clinical trial will compare regional citrate anticoagulation (RCA) and standard heparin anticoagulation (HA) during postdilution hemodiafiltration (HDF) in chronic dialysis patients with end-stage kidney disease.\n\nThe primary aim of the study is to evaluate biocompatibility during HDF by measuring markers of complement activation (C3a), platelet activation (PF4), and coagulation activation (thrombin-antithrombin complex, TAT).\n\nSecondary aims include comparison of solute removal efficiency, including beta-2 microglobulin, phosphate, and urea removal, as well as assessment of citrate, calcium, and magnesium kinetics during citrate anticoagulation.\n\nTwenty adult chronic dialysis patients will undergo two study HDF procedures in randomized order: one procedure using heparin anticoagulation and one procedure using regional citrate anticoagulation with a one-week interval between procedures.\n\nThe study aims to improve understanding of the effects of anticoagulation methods on hemodiafiltration biocompatibility and dialysis efficiency and may contribute to optimization of citrate anticoagulation protocols in chronic hemodiafiltration patients.",[27,28,29,30],"End-Stage Kidney Disease","Hemodiafiltration","Chronic Hemodialysis","Renal Failure",[32,33,28,34,35,36,37,38,39,40,41],"Citrate anticoagulation","Heparin anticoagulation","Dialysis","Biocompatibility","Beta-2 microglobulin","Complement activation","Regional citrate anticoagulation","Chronic dialysis","Thrombin-antithrombin complex","Platelet factor 4","NOT_YET_RECRUITING","2026-05-27",{"date":45,"type":46},"2026-06-01","ACTUAL",{"date":48,"type":21},"2026-06-05",{"date":50,"type":21},"2027-04-01",{"name":52,"class":53},"University Medical Centre Ljubljana","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100502943","incremental-hemodialysis-the-twoplus-trial-100502943","NCT05828823","Incremental Hemodialysis: The TwoPlus Trial","Comparative Effectiveness of an Individualized Model of Hemodialysis Versus Conventional Hemodialysis","Patient eligibility Criteria:\n\nInclusion Criteria:\n\n* Clinical Inclusion Criteria:\n* Age ≥ 18 years\n* Incident kidney dysfunction requiring dialysis (KDRD) started on maintenance, in-center hemodialysis (HD), or anticipated to be started on maintenance, in-center HD within the next 12 weeks\n* Has received ≤36 sessions of intermittent HD (i.e., on HD for ≤12 weeks) at the time patient is approached for potential study participation\n\nResidual Kidney Function Inclusion Criteria:\n\n* Kidney urea clearance \\\u003C2.0 mL\u002Fmin\n* Urine volume# of ≥500 mL\u002F24 h\n\nExclusion Criteria:\n\n* Pre-HD serum K ≥5.8 mEq\u002FL, Na ≤125 mEq\u002FL, or bicarbonate level ≤17 mEq\u002FL\n* Requirement or anticipated requirement of high-volume ultrafiltration\n* Unable or unwilling to follow the study protocol for any reason\n* Known pregnancy or planning to attempt to become pregnant or lactating women\n* Estimated survival or dialysis modality change or center transfer \\\u003C6 months\n\nCaregiver Eligibility Criteria:\n\n* be at least 18 years old\n* be the main caregiver (at patient's choice)\n* be a close relative of the patient (spouse, child, sibling, parent, grandchild)\n* have no known psychiatric and neurologic disorders (through direct inquiry from the person)\n* not be a member of the medical or healthcare team\n* not be the caregiver for another patient with chronic illness\n* not have experienced severe life events within prior 3 months of enrollment (through direct inquiry from the person)",{"count":63,"type":21},350,[24],"This study is to prospectively compare clinical effectiveness between clinically- matched incremental hemodialysis and conventional hemodialysis in patients with incident kidney dysfunction requiring dialysis and residual kidney function.\n\nThe study will enroll 350 patients on chronic hemodialysis and 140 caregivers of enrolled patients. Patients will be randomized in 1:1 ratio to either incremental start hemodialysis or conventional hemodialysis. Caregivers will be followed along with patients for an average period of 2 years post randomization.",[27],[68,69],"Hemodialysis","Clinically-Matched Incremental Hemodialysis","RECRUITING","2026-05-20",{"date":73,"type":46},"2026-05-22",{"date":75,"type":46},"2024-02-26",{"date":77,"type":21},"2031-01",{"name":79,"class":53},"Wake Forest University Health Sciences",10,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":54},"100494256","phase-3-mechanisms-and-safety-of-sglt2-inhibition-in-peritoneal-dialysis-100494256","NCT05715814","meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis","A Single Arm, Open Label, Pilot Study to Evaluate the Safety and Efficacy of Once Daily 25mg Empagliflozin in Patients on Peritoneal Dialysis With Residual Kidney Function","CANARY","Inclusion Criteria:\n\n* Signed and dated written informed consent.\n* Patients aged ≥18 years on PD with RKF defined as at least 250 cc of urine output per day (assessed via 24-hour urine collection) and a minimum measured GFR of 2 ml\u002Fmin\u002F1.73m2, as measured at least once in the last 3 months.\n* Stable PD prescription, as determined by investigators.\n* Stable dose of RAAS blockade if on a medication within this class for the last 30 days.\n\nExclusion Criteria:\n\n* Type 1 diabetes.\n* Recent (in the 30 days prior to screening) acute coronary syndrome or cerebrovascular event.\n* PD peritonitis within 30 days of screening.\n* History of organ transplant, including pancreas, pancreatic islet cells or kidney transplant.\n* Planned surgery\u002Fprocedures or radiologic investigations requiring contrast during the trial.\n* Pregnant, planning to become pregnant, or nursing an infant during the study period\n* History of any DKA event\n* Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (e.g., malaria, babesiosis, hemolytic anemia) at screening.\n* Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial.\n* Alcohol or drug abuse within the 3 months prior to screening that would interfere with trial participation based on Investigator's judgement.\n* Use of SGLT2 inhibitor within 30 days prior to screening.\n* Intake of an investigational drug in another trial within 30 days prior to screening.\n* Patient not able to understand and comply with study requirements, based on Investigator's judgment.\n* Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcome (e.g. immunocompromised patients, active malignancy, patients who might be at higher risk of developing genital or mycotic infections, patients with chronic viral infections, uncontrolled hypertension, cardiorenal and\u002For hepatorenal syndrome, severe hepatic impairments etc.).",{"count":20,"type":21},[91],"PHASE3","The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).",[94,95,96,97,98],"Peritoneal Dialysis Complication","End Stage Kidney Disease","Sodium-glucose Co-transporter-2 Inhibitors","Kidney Dysfunction","Residual Kidney Function","2026-04-30",{"date":101,"type":46},"2026-05-01",{"date":103,"type":46},"2024-09-01",{"date":105,"type":21},"2027-12-01",{"name":107,"class":53},"University Health Network, Toronto",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":54},"100543461","virtual-reality-in-end-stage-kidney-disease-100543461","NCT06356168","Virtual Reality in End Stage Kidney Disease","Social Virtual Reality to Alleviate Loneliness and Symptoms for Individuals Receiving Hemodialysis","Inclusion Criteria\n\n* Diagnosis of end stage kidney disease with hemodialysis 3 times per week for at least 1 month\n\nExclusion Criteria\n\n* Acutely ill\n* Active nausea\n* Epilepsy",{"count":116,"type":21},60,[24],"The goal of this clinical trial to compare the social virtual reality and individual virtual reality in patients with end stage kidney disease who are hemodialysis. The main aim is to determine if there are differences in symptoms between the groups. Participants will use virtual reality glasses for 30-45 minutes during dialysis sessions for 4 weeks.",[95],"2026-03-31",{"date":122,"type":46},"2026-04-06",{"date":124,"type":46},"2026-03-30",{"date":126,"type":21},"2026-07-31",{"name":128,"class":53},"University of Pennsylvania",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":136,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":159},"100625726","phase-1-a-study-of-eloralintide-ly3841136-in-participants-with-renal-impairment-and-in-participants-with-normal-renal-function-100625726","NCT07426380","A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function","A Phase 1, Multicenter, Parallel-Design, Single Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Eloralintide in Participants With Severe Renal Impairment and End Stage Renal Disease (ESRD) Compared With Participants With Normal Renal Function","Inclusion Criteria:\n\n* Have a body weight of 55 kilograms (kg) or more and a body mass index (BMI) within the range of 19.0 to 40.0 kilograms per square meter (kg\u002Fm²), inclusive\n* Have no significant history of spontaneous or ethanol-induced hypoglycemia\n\nAdditional Inclusion Criteria for Group 1\n\n* Are healthy as determined by medical history, physical examination, and other screening procedures, with normal renal function, assessed by estimated glomerular filtration rate (eGFR) of at least 90 milliliters per minute (mL\u002Fmin)\n* Have glycated hemoglobin (HbA1c) less than or equal to 6.5% at screening\n\nAdditional Inclusion Criteria for Groups 2 and 3\n\n* Have stable severe renal impairment, assessed by eGFR less than 30 mL\u002Fmin at screening or with end-stage renal disease (ESRD) who have been on a stable hemodialysis (HD) schedule for at least 3 months prior to planned dosing\n* Have acceptable blood pressure and pulse rate\n* If participants have Type 2 Diabetes Mellitus (T2DM), they must have a HbA1c equal to or less than 10.0% at screening\n\nExclusion Criteria:\n\n* Have a history of chronic liver disease, acute or chronic hepatitis, including a history of autoimmune hepatitis, any evidence for hepatic impairments\n* Have a current, functioning organ transplant. Nonfunctional renal allografts may be considered\n* Have significant history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, dermatological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the investigational product; or interfering with the interpretation of data\n\nGroups 2 and 3\n\n* Are receiving continuous HD or peritoneal dialysis.\n* Have used any drug indicated for medical care of the participant's renal impairment, which is not established in dose and administered for at least 7 days before eloralintide administration",true,"85 Years",{"count":139,"type":21},28,[141],"PHASE1","The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin).\n\nFor each participant, the study will last about 14 weeks, excluding screening.",[144,145,146,147,148,95],"Kidney Disease","Renal Insufficiency Chronic","Kidney Failure, Chronic","Renal Impairment","Renal Insufficiency","2026-03-12",{"date":151,"type":46},"2026-03-13",{"date":153,"type":46},"2026-02-24",{"date":155,"type":21},"2026-10",{"name":157,"class":158},"Eli Lilly and Company","INDUSTRY",2,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":167,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":54},"100482149","potassium-containing-salt-substitute-in-hemodialysis-dependent-end-stage-kidney-disease-100482149","NCT05558267","Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease","A Randomized, Pilot, Double-Blind Crossover Trial of a Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease","Inclusion Criteria:\n\n1. Receiving outpatient maintenance HD therapy.\n2. Age ≥ 21 years.\n3. Negative serum pregnancy test for women of child-bearing capacity. Childbearing capacity will be defined by report of menstruation within ≤ 6 months.\n\nExclusion Criteria:\n\n1. Currently incarcerated.\n2. Insufficient capacity for informed consent.\n3. Non-hemolyzed serum potassium concentration \\>6.0 mEq\u002FL within ≤30 days.\n4. Unscheduled HD for hyperkalemia within ≤30 days.\n5. Attendance at ≤10 of last 13 scheduled OP HD sessions.\n6. Co-habiting family member with known hyperkalemia.\n7. Co-habiting family with ≥stage 3b chronic kidney disease or chronic kidney disease of unknown severity.\n8. Hemoglobin \\\u003C 8.0 mg\u002FdL.\n9. Use of other potassium supplements.","21 Years",{"count":20,"type":21},[24],"16 individuals with hemodialysis-dependent end stage kidney disease will receive 16 days of a potassium-containing salt-substitute and 16 days of standard table salt in random order. There will be a 19 day wash out period between the salt-substitute and table salt periods. Potassium concentration will be measured bi-weekly prior to HD each week during intervention. The primary endpoint will be the change in potassium from baseline. Additional measurements will include assessment of dietary intake, ambulatory blood pressure, occurrence of peri-dialytic symptoms, and per-dialytic vital signs.",[95],[173],"Potassium-Containing Salt Substitute","2026-03-10",{"date":149,"type":46},{"date":177,"type":21},"2027-01-15",{"date":179,"type":21},"2027-06-15",{"name":181,"class":53},"NYU Langone Health",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":213},"100510810","phase-3-csp-2026---beta-blocker-dialyzability-on-cardiovascular-outcomes-100510810","NCT05931276","CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes","CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (BRAVO)","BRAVO","Inclusion Criteria:\n\n* On hemodialysis\n* Received one of the following beta blockers through the VA pharmacy: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, bisoprolol\n\nExclusion Criteria:\n\n* Impaired decision-making capacity\n* Patients not receiving carvedilol who have a history of asthma\n* known hypersensitivity to any component of either drug\n* Provider unwilling to sign a new medication order for a randomized patient\n* No surrogate consent will be allowed",{"count":191,"type":21},2540,[91],"The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.",[27,195],"End-Stage Renal Disease",[34,197,198,199,200,201,202,68],"beta-Blockers, Adrenergic","Cardiovascular Diseases","Point of Care Research","Comparative Effectiveness Research","Metoprolol Succinate","Carvedilol","2026-01-07",{"date":205,"type":46},"2026-01-09",{"date":207,"type":46},"2024-05-22",{"date":209,"type":21},"2028-12-31",{"name":211,"class":212},"VA Office of Research and Development","FED",8,{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":136,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":223,"conditions":224,"keywords":228,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":54},"100479632","phase-1-delayed-immunological-tolerance-in-patients-with-well-functioning-pre-existing-hla-matched-kidney-transplants-100479632","NCT05525507","Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants","A Single-armed, Unblinded, Non-randomized Feasibility Study of Hematopoietic Stem Cell Infusion Following a Conditioning Regimen of Total Lymphoid Irradiation (TLI) and Anti-thymocyte Globulin (ATG) in Patients With a Pre-existing, Well-functioning HLA-matched Kidney Transplant","Recipient Inclusion Criteria:\n\n1. Males and females ages 18 years and older with a pre- existing kidney transplant from an HLA-matched living donor.\n2. Pre-existing living kidney transplant must be within 3 months to 5 years from date of scheduled HPSC infusion.\n3. No history of rejection with current HLA matched kidney transplant.\n4. Recipient is without post-transplant major complications, including de novo malignancy, active infection or rejection.\n5. Stable renal function determined per investigator discretion.\n6. Agreement to participate in the study and ability to give informed consent.\n7. Meets institutional criteria for HSPC infusion.\n8. Resides or is willing to stay within 3 hours distance from UCLA Medical Center by ground transportation for the first three to six months of the trial at the physician's discretion.\n9. No known contraindication to administration of rATG or radiation.\n10. If participant is a female of reproductive potential (i.e., no documented absence of ovaries or uterus, history of tubal ligation, or post-menopausal status) participant must be confirmed not pregnant by a serum or urine pregnancy test) and must agree to practice a reliable form of contraception including hormonal treatments, barrier methods or intrauterine device for at least 12 months post-transplant.\n11. Karnofsky Performance Score (KPS) ≥ 70.\n12. Adequate cardiac function defined as left ventricular ejection fraction (LVEF) ≥ 40% by MUGA (Multi Gated Acquisition) scan or echocardiogram.\n13. Adequate liver function defined as total bilirubin ≤ 1.5 times the upper limit of normal and AST\u002FALT ≤ 2.0 times the upper limit of normal.\n14. Adequate social support based on evaluation by the UCLA bone marrow and\u002For renal transplant team.\n\nRecipient Exclusion Criteria:\n\n1. Donor is identical twin.\n2. Major ABO incompatibility with donor\n3. Positive HLA Donor-Specific Antibody (DSA)\n4. History of multi-organ transplantation\n5. History of rejection with current HLA-matched kidney transplant\n6. Known allergy to rabbit proteins\n7. History of post-transplant major complications, including de novo malignancy, active\u002Fchronic infection or rejection, with the exception of low risk, early-stage malignancy with\n\n   ≥90% 5-year survival not receiving chemotherapy or immunotherapy and non-melanomatous skin cancer.\n8. History of active malignancy within the past 5 years with the exception:\n\n   1. Low risk cancer on active surveillance\n   2. Malignancy treated with curative intent with no known active disease \\>2 years before the first dose of study treatment and of low potential risk for recurrence\n   3. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n   4. Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ, and DCIS)\n9. Worsening renal functioning over preceding 3-month interval determined per investigator discretion.\n10. Pregnant (confirmed by urine or serum pregnancy test) or lactating.\n11. Leukopenia (with a white blood cell count \\\u003C 3,000\u002FµL) or thrombocytopenia (with a platelet count \\\u003C 70,000\u002FµL).\n12. EBV, CMV and BK PCR negative at time of HPSC infusion is preferred, but if they have had a history of + CMV\u002FBK PCR, it should be resolved by 3 months.\n13. Active bacterial, fungal, mycobacterial, or viral infection (including active hepatitis B and\u002For C).\n14. Seropositivity for HIV 1 or 2 by 4th generation serum antibody\u002Fantigen testing, or HTLV I or II by serum antibody testing.\n15. Renal disease with high risk of recurrence (i.e., focal segmental glomerulosclerosis).\n16. Advanced hepatic fibrosis or cirrhosis secondary to hepatitis B and\u002For C diagnosis.\n17. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia; active extra-renal autoimmune disease requiring immunosuppression.\n18. Active extra-renal autoimmune disease requiring immunosuppression.\n19. Neuropsychiatric illness that precludes the ability to give informed consent and\u002For places the participant as high risk for non-compliance with the safety monitoring requirements of the study.\n20. May not have received other immunomodulatory agents, including but not limited to tumor necrosis factor inhibitors within six months of the study treatment. Use of corticosteroids prescribed for a time-limited indication (\\\u003C\u002F= 4 weeks) and stopped at least 4 weeks before the kidney transplant is acceptable.\n21. May not have received immunotherapy drugs such as immune checkpoint inhibitors (e.g. pembrolizumab, nivolumab, and ipilimumab), tumor necrosis factor inhibitors, rituximab, and interleukin-2 within six months of the study treatment.\n22. Current or active abuse of alcohol and\u002For drugs within last 6 months.\n23. Body Mass Index (BMI) ≥ 40.\n\nDonor Inclusion Criteria:\n\n1. HLA-matched sibling on high-resolution HLA typing who\n\n   a. is ≥18 years of age.\n2. Must meet institutional criteria for HSPC transplant donation.\n3. Medically fit to tolerate peripheral blood apheresis, including weighing ≥110 pounds, hemoglobin ≥11, white blood cell count ≥ 3,000\u002FµL, and platelets ≥ 100,000\u002FµL.\n4. Serum creatinine as expected post-kidney donation and coagulation parameter studies; or, if abnormal, the changes are not considered clinically significant.\n\nDonor exclusion criteria:\n\n1. Recipient is identical twin.\n2. Major ABO incompatibility with recipient.\n3. Medically unfit to tolerate peripheral blood apheresis (e.g. small body size, poor vascular access, not a suitable candidate for placement of a central catheter).\n4. Pregnant (confirmed by urine or serum pregnancy test) or lactating.\n5. Seropositivity for HIV 1 or 2 by 4th generation serum antibody\u002Fantigen testing, HTLV I or II by serum antibody testing\n6. Active West Nile Virus infection.\n7. Active bacterial, fungal, mycobacterial or viral infection (including active hepatitis B and\u002For C).\n8. Psychiatric, addictive, neurological, or other disorder that compromises ability to give true informed consent for participation in this study.\n9. History of active malignancy within the past 5 years with the exception:\n\n   1. Low risk cancer on active surveillance\n   2. Malignancy treated with curative intent with no known active disease \\>2 years before the first dose of study treatment and of low potential risk for recurrence\n   3. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n   4. Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ, and DCIS)\n10. No use of oral anticoagulants 2 days prior to apheresis. Note: Use of aspirin and non-steroidal anti-inflammatory drugs, for pain and inflammation management purposes, are permitted to enroll in the study, but these drugs must be stopped 7 days prior to apheresis, however subjects who are taking aspirin for its anti- platelet\u002Fanti-thrombotic effect, are excluded.",{"count":80,"type":21},[141],"The study seeks to determine if patients with a pre-existing, well-functioning kidney transplant from a HLA-identical living donor can be withdrawn from immunosuppressive medications without compromising allograft function through hematopoietic stem cell (HPSC) infusion from the same donor. HPSC infusion will be preceded by a conditioning regimen of total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG).",[95,225,226,227],"Immunological Tolerance","Kidney Transplant Failure and Rejection","Chronic Kidney Diseases",[229,230,231,232,233,234],"immunological tolerance","kidney transplant","tolerance","end stage kidney disease","end stage renal disease","chronic kidney disease","2025-11-21",{"date":237,"type":46},"2025-11-26",{"date":239,"type":46},"2022-12-21",{"date":241,"type":21},"2026-12",{"name":243,"class":53},"University of California, Los Angeles",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":257,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":54},"100495986","symptom-monitoring-in-hemodialysis-100495986","NCT05738330","Symptom Monitoring in Hemodialysis","Comparative Effectiveness of Two Approaches to Symptom Monitoring in Hemodialysis","SMaRRT-HD","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Treatment with hemodialysis at a participating dialysis clinic\n* English or Spanish speaking\n\nExclusion Criteria:\n\n* Not willing to report their symptoms using the SMaRRT-HD platform\n* Not willing to share clinically acquired data with the research team\n* Underlying condition such as dementia that is anticipated to prevent comprehension of the trial information document (fact sheet)\n* Incarceration",{"count":253,"type":21},2400,[24],"The SMaRRT-HD trial is a cluster randomized trial of symptom monitoring with supported clinician follow-up using the SMaRRT-HD electronic patient reported outcome measure (ePROM) system versus Usual Care. Approximately 2400 patients at up to 36 geographically and racially diverse US hemodialysis clinics will be enrolled. The primary trial hypothesis is that regular symptom patient reported outcome measure (PROM) administration with supported clinician follow-up in dialysis care will reduce suffering and improve outcomes by prompting treatment of unrecognized symptoms, and enhancing patient-care team communication. Clinics randomized to the SMaRRT-HD group will adopt the use of SMaRRT-HD for 12 months. SMaRRT-HD is a symptom monitoring system that includes 1) tablet-based symptom reporting using a PROM and 2) supported clinician follow-up consisting of symptom alerts, guidances for symptom management, and symptom tracking reports that are shared with patients. Dialysis clinics randomized to Usual Care will not adopt SMaRRT-HD or any other trial-driven procedures. Usual Care clinics will monitor symptoms through clinical care interactions with participants and by administering a Health Related Quality of Life survey that includes questions about symptoms.",[95],[258,259,68,34,260,261],"End stage kidney disease","Kidney","Symptom monitoring","Electronic Patient-Reported Outcome Measure (ePROM)","2025-11-18",{"date":264,"type":46},"2025-11-24",{"date":266,"type":46},"2023-06-24",{"date":268,"type":21},"2027-09",{"name":128,"class":53},{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":283,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":295,"locationsCount":297},"100563238","moda-flx-hemodialysis-system-under-professional-care-settings-by-trained-individuals-and-at-home-by-participants-100563238","NCT06613568","Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants","Prospective, Non-Randomized, Multicenter, Open-Label Study Evaluating the Use of the Moda-flx Hemodialysis System™ Under Professional Care and At Home by Participants With End Stage Kidney Disease (ESKD) Who Are on Stable Dialysis Regimens","Inclusion Criteria:\n\n* Are between 18 and 80 years of age and Care Partner is at least 18 years of age at the time of signing consent.\n* Have a diagnosis of end stage kidney disease (ESKD) adequately treated by maintenance dialysis (defined as achieving a spKt\u002FV ≥ 1.2 OR stdKt\u002FV ≥ 2.1) and be deemed stable by their treating nephrologist prior to the end of the Screening Period\n* Have a well-functioning and stable vascular access (tunneled central venous catheter arteriovenous fistula, or graft) that allows a blood flow of at least 300 ml\u002Fmin prior to the end of Screening\n* Can successfully complete a Skills and Comprehension Assessment with a Care Partner prior to the completion of the Training Period.\n\nExclusion Criteria:\n\n* Hgb level of \\\u003C 9 g\u002FdL at Screening\n* Symptomatic intradialytic hypotension requiring medical intervention (ultrafiltration turned off, bolus of fluid) in at least two treatments during the Run-In period defined as:\n\n  1. Persistent pre-dialysis sitting SBP \\\u003C 100 mmHg despite medical therapy,\n  2. Nadir intradialytic Systolic Blood Pressure (SBP) \\\u003C 90 mmHg, if Subject's pre-HD SBP \\\u003C 160 mmHg\n  3. Nadir intradialytic SBP \\\u003C 100 mmHg if Subject's pre-HD SBP ≥ 160 mmHg\n* Documented history of non-adherence to dialysis therapy that would prevent successful completion of the study\n* Participant had an average ultrafiltration rate \\> 13 mL\u002Fkg\u002Fhour during the last 2 weeks prior to Screening, per medical records.\n* Had a significant cardiovascular adverse event within the last 90 days prior to Screening.","80 Years",{"count":279,"type":21},50,[24],"The purpose of this study is to evaluate the safety and efficacy of the Moda-flx Hemodialysis System™ when used Under Professional Care Settings by trained individuals and At Home by trained Participants and Care Partners",[95],[284,285,286,34,287,288,148,146],"Renal Disease","Hemodialysis Complication","Kidney Diseases","Renal Dialysis","Hemodialysis, Home","2025-11-05",{"date":291,"type":46},"2025-11-10",{"date":293,"type":46},"2025-10-06",{"date":268,"type":21},{"name":296,"class":158},"Diality Inc.",4,{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":17,"minAge":167,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100596897","the-reducing-adverse-outcomes-in-dialysis-by-adjusting-the-prescription-for-dialysate-potassium-trial-100596897","NCT07051447","The Reducing Adverse Outcomes in Dialysis by Adjusting the pRescription for Dialysate Potassium Trial","The Reducing Adverse Outcomes in Dialysis by Adjusting the pRescription for Dialysate Potassium Trial (RADAR-K): A Randomized, Controlled, Pilot Trial Comparing Usual Care to a Precision Approach to Dialysis Potassium Prescribing.","RADAR-K","Inclusion Criteria:\n\n* Undergoing in-center, 3x\u002Fweekly HD for treatment of end-stage kidney disease (ESKD) for at least 90 days\n* Age at least 21 years\n* Prescribed HD time up to 15 hours\u002F week\n\nExclusion Criteria:\n\n* Incarcerated\n* Life expectancy of 1 year or less\n* Kidney transplant, transition to home dialysis, or transfer to non-participating HD unit anticipated within 6 months or less\n* Cognitive condition that precludes consent\n* Severe anemia (hemoglobin \\\u003C 8.0 g\u002FdL) within 30 days\n* K concentration of 7.0 mEq\u002FL or more within 60 days\n* Pregnant women\n* Women of childbearing potential actively trying to conceive unwilling to use contraception\n* Participation in other interventional studies within 30 days prior to enrollment",{"count":307,"type":21},120,[24],"This will be a randomized controlled pilot trial comparing usual care to a precision approach to dialysis potassium prescribing. The precision approach will incorporate point of care testing of blood potassium concentration prior to each dialysis session and adjustment of the dialysate K prescription with a blood-dialysate K gradient minimization strategy (PKRxHD).",[95],"2025-06-26",{"date":313,"type":46},"2025-07-04",{"date":315,"type":21},"2025-08-01",{"date":317,"type":21},"2029-08-01",{"name":181,"class":53},{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":22,"phases":326,"briefSummary":327,"conditions":328,"keywords":332,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":54},"100583503","staged-kidney-transplantation-during-combined-heartkidney-transplantation-100583503","NCT06877169","Staged Kidney Transplantation During Combined Heart\u002FKidney Transplantation","Inclusion Criteria:\n\n* Adult patients (18 years or older) undergoing combined heart and kidney transplantation at Cedars-Sinai Medical Center.\n\nExclusion Criteria:\n\n* Patients who undergo simultaneous heart\u002Fkidney transplantation in a single operative event due to medical necessity will be excluded.\n* Patients with medical records flagged as \"break-the-glass\" or \"research opt-out\" within the center's electronic health record.",{"count":20,"type":21},[24],"The primary purpose of this study is to evaluate the safety and efficacy of ex vivo machine perfusion with staged implantation of kidney allografts during combined heart\u002Fkidney transplantation.",[329,330,331],"Heart Failure","Chronic Kidney Disease","End-stage Kidney Disease",[333,334,335,336],"combined heart and kidney transplant","simultaneous heart and kidney transplant","hypothermic oxygenated machine perfusion","organ preservation","2025-05-29",{"date":339,"type":46},"2025-06-03",{"date":341,"type":46},"2025-04-07",{"date":343,"type":21},"2035-02-28",{"name":345,"class":53},"Cedars-Sinai Medical Center",{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":356,"phases":4,"briefSummary":357,"conditions":358,"keywords":360,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":54},"100330767","validating-novel-non-contrast-cardiac-mri-imaging-in-haemodialysis-patients-100330767","NCT03586518","Validating Novel, Non-contrast Cardiac MRI Imaging in Haemodialysis Patients","Validating the Accuracy of Novel, Non-contrast, Cardiac Magnetic resOnaNce Imaging in Defining Myocardial FIbRosis in Patients With End-stage Renal Disease on haeModialysis: the CONFIRM Study","CONFIRM","Inclusion Criteria:\n\n* Prevalent haemodialysis patient (more than 3 months)\n* Active on the supportive care register with anticipated death in the subsequent 12 months\n* Able to give informed consent\n* Consent to donation of heart for research following death\n* Able to understand written and verbal explanations in English\n\nExclusion Criteria:\n\n* Contraindication to MRI scan (e.g. pacemaker, incompatible metallic implants, claustrophobia)\n* Patients with expected or potential infiltrative cardiomyopathy (e.g. amyloidosis)\n* Unable to give informed consent\n* Unable to understand written and verbal explanations in English",{"count":355,"type":21},9,"OBSERVATIONAL","There are currently no good ways of measuring levels of scarring in the hearts of patients with advanced kidney disease and patients on dialysis, although recent research has shown a new cardiac MRI technique, called native T1 mapping, may provide a solution to this. To assess the accuracy of this novel technique in dialysis patients, it is essential to undertake a study which compares native T1 mapping to actual levels of scarring in the hearts of patients on dialysis.",[95,359],"Fibrosis Myocardial",[361,68,362,363],"Cardiac MRI","Myocardial Fibrosis","Myocardial Inflammation","2025-04-15",{"date":366,"type":46},"2025-04-18",{"date":368,"type":46},"2019-11-03",{"date":370,"type":21},"2025-12-31",{"name":372,"class":53},"University of Leicester",{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":22,"phases":382,"briefSummary":384,"conditions":385,"keywords":386,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":396,"locationsCount":398},"100272258","phase-4-randomised-evaluation-of-sodium-dialysate-levels-on-vascular-events-100272258","NCT02823821","Randomised Evaluation of Sodium Dialysate Levels on Vascular Events","RESOLVE","The site inclusion criteria are:\n\n* Predominantly dialyses adults (≥18 years old) receiving maintenance haemodialysis\n* Rates of withdrawal within the first two years of commencing dialysis for social reasons have been less than 15% for the 2 years prior to recruitment and are not expected to increase above 15%\n* Has a minimum of 10 dialysis recipients at time of randomisation\n* Utilises a default dialysate sodium concentration at the time of recruitment (a substantial majority of dialysis sessions are conducted with the default dialysate sodium concentration)\n* Is a self-contained unit (i.e. unit patients do not regularly rotate through another unit. Brief trips by patients to a parent or other unit do not exclude a site)\n* Willing to accept randomisation to either intervention (as determined by nominated Director of Unit)\n* Is not a home dialysis training or support unit. \\[Sites that include both in-center\u002Fsatellite dialysis patients and home patients may participate but the study procedures and assessments will only be conducted in the incenter\u002Fsatellite component of the site\\].\n\nThe exclusion criteria are:\n\n* Not able to comply with data collection methods",{"count":381,"type":21},50000,[383],"PHASE4","This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol\u002Fl and 137mmol\u002Fl, on major cardiovascular events and death in patients receiving maintenance haemodialysis.",[27],[27,68,387,388,389,34,378],"Dialysate","Sodium","Cluster-randomisation","2025-04-01",{"date":392,"type":46},"2025-04-04",{"date":394,"type":46},"2016-06",{"date":241,"type":21},{"name":397,"class":53},"University of Sydney",264,{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":136,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":356,"phases":4,"briefSummary":408,"conditions":409,"keywords":410,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":54},"100374826","duke-apol1-research-biorepository-100374826","NCT04160507","Duke APOL1 Research Biorepository","DARB","Inclusion Criteria:\n\n* Majority of subjects recruited for this study will be self-identified African Americans, Afro-Caribbean and other black individuals. Study subjects will include individuals at various stages of kidney disease and those without any clinical evidence of kidney disease.\n* Healthy black adults, age 50 and older with no known history of kidney disease will be recruited as controls\n\nExclusion Criteria:\n\n* Black adult cases with diabetic nephropathy\n* Healthy controls with kidney disease",{"count":407,"type":21},200,"The Duke ApoL1 Nephropathy Biorepository aims to address needs within non-diabetic kidney failure research by utilizing existing and, when necessary, developing new infrastructure to support the consent of patients and the collection of dedicated samples for ApoL1 Nephropathy biorepository.\n\nThe mutations in ApoL1 gene that are strongly associated with kidney disease are only present in individuals of recent African ancestry (i.e., black people). Caucasians do not have these ApoL1 mutations nor the associated kidney disease. Therefore, majority of subjects recruited for this study will be self-identified African Americans, Afro-Caribbean and other black individual. Study subjects will include individuals with end stage kidney disease and those without any clinical evidence of kidney disease.\n\nAdditionally, healthy black adults with no known history of kidney disease will be recruited as controls in this study because they are the only group that can fill this role.",[95],[411,412,144],"ESKD","APOL 1 gene","2025-03-14",{"date":415,"type":46},"2025-03-18",{"date":417,"type":46},"2019-12-13",{"date":419,"type":21},"2026-11-15",{"name":421,"class":53},"Duke University",{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":22,"phases":431,"briefSummary":432,"conditions":433,"keywords":434,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":443,"locationsCount":54},"100488595","hemodynamics-in-chronic-hemodialysis-patients-undergoing-isolated-ultrafiltration-compared-to-conventional-hemodialysis-100488595","NCT05642156","Hemodynamics in Chronic Hemodialysis Patients Undergoing Isolated Ultrafiltration Compared to Conventional Hemodialysis","ISO-UF","Inclusion Criteria:\n\n* Written consent of the participant after being informed\n* At least 18 years of age\n* End stage kidney disease patient undergoing hemodialysis\n* Dry weight stable for a minimum of one month\n* Interdialytic weight gain of \\>2 liters in the short interdialytic interval\n\nExclusion Criteria:\n\n* No informed consent was obtained\n* Patients with a pacemaker or implanted medical device that prevents compliance with study regulations\n* Patients treated with hemodiafiltration\n* Patients treated with medium cut-off membranes (Theranova, Baxter)\n* Patients with recurrent severe hyperkalemia after the short interdialytic interval (K+ concentration \\> 6.0 mmol\u002FL, requiring more than 2 hours of dialysis to ameliorate the post-dialytic shift from other compartments.\n* Women of childbearing age not using contraception",{"count":430,"type":21},32,[24],"Patients treated with hemodialysis (HD) bear increased risk of cardiovascular events, which results in high morbidity and mortality among this cohort of patients. Intradialytic hypotension (IDH), which is an independent risk factor for mortality, occurs in up to 20% of hemodialysis session and may lead to myocardial stunning and cerebral ischemia resulting in increased white matter lesions, gastrointestinal ischemia and shunt vessel thrombosis. Due to the deleterious effects of IDH during HD, preventive measurements such as limiting interdialytic weight gain are recommended, but frequently fluid and salt restriction are not adhered to, thus increasing dialysis time or frequency of treatments is a common strategy in those patients.",[95],[435,436],"hemodialysis","ultrafiltration","2025-03-03",{"date":439,"type":46},"2025-03-04",{"date":441,"type":46},"2022-11-02",{"date":370,"type":21},{"name":444,"class":53},"Medical University of Graz",{"id":446,"slug":447,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":356,"phases":4,"briefSummary":454,"conditions":455,"keywords":457,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":54},"100569948","evaluation-of-igra-symptoms-and-chest-radiograph-for-subclinical-tb-detection-in-esrd-and-kt-100569948","NCT06700876","Evaluation of IGRA, Symptoms and Chest Radiograph for Subclinical TB Detection in ESRD and KT","Evaluation of Interferon-gamma Release Assays, Symptom Screening and Chest Radiograph for Detection of Subclinical Tuberculosis of End-stage Kidney Disease and Kidney Transplant Recipients in Thailand","Inclusion Criteria:\n\n1. End-stage renal disease on renal replacement therapy (hemodialysis or peritoneal dialysis) or status-post-living donor or deceased donor kidney transplantation\n2. Aged more than or equal 18 years\n\nExclusion Criteria:\n\n1. Positive PPD test or a previously documented positive PPD\n2. Active pulmonary or extrapulmonary tuberculosis",{"count":453,"type":21},160,"This is an observational study among approximately 160 end-stage renal disease patients on renal replacement therapy and post-living donor or deceased donor kidney transplant recipients. Investigators aim to assess the proportion of positive IGRA associated with symptom development, sputum Xpert MTB\u002FRIF assay, and chest radiograph to define latent TB infection and subclinical TB among ESKD and renal transplant patients.",[456,27],"Tuberculosis (TB)",[458,459,331,460,461,462],"Subclinical Tuberculosis","Interferon gamma release assays","Detection of Subclinical Tuberculosis","Tuberculosis","IGRAs","2024-11-20",{"date":465,"type":46},"2024-11-22",{"date":467,"type":46},"2024-08-06",{"date":469,"type":21},"2027-06-30",{"name":471,"class":53},"Mahidol University",{"id":473,"slug":474,"hasResults":11,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":22,"phases":480,"briefSummary":481,"conditions":482,"keywords":483,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":54},"100563902","the-effect-of-mindfulness-on-emotional-regulations-skills-and-quality-of-life-among-patients-on-hemodialysis-100563902","NCT06622200","The Effect of Mindfulness on Emotional Regulations Skills and Quality of Life Among Patients on Hemodialysis","The Effects of Mindfulness-based Intervention on Trait Mindfulness, Cognitive Reappraisal, Behavioral Suppression, and Quality of Life Among Patients Undergoing Hemodialysis.","Inclusion Criteria:\n\n* Patients with ESRD undergoing hemodialysis at least three sessions a week\n* Being at least 18 years old\n* Having a smartphone\n* Being capable of reading and writing in Arabic\n\nExclusion Criteria:\n\n* Patients under psychotherapy or taking regular psychopharmacological and analgesic treatment",{"count":307,"type":21},[24],"The study aims to investigate how mindfulness-based intervention (MBI) impacts trait mindfulness, cognitive reappraisal, expressive suppression and quality of life in patients with end-stage renal disease (ESRD) undergoing hemodialysis.\n\nA Randomized controlled trial will be conducted with patients diagnosed with ESRD and undergoing hemodialysis treatment. Participants selected using a convenience sampling method will be randomly assigned into the intervention group (n=52) who received MBI, and the control group (n=52) who received a similar intervention after the study. The intervention involves a 30-minute MBI introduced three sessions per week during hemodialysis sessions over five weeks. Outcome measures included the Mindful Attention Awareness Scale (MAAS) to assess trait mindfulness, the Emotion Regulation Questionnaire (ERQ) for cognitive reappraisal and behavioral suppression, and the Kidney Disease-related Quality of Life Questionnaire for quality of life. Data were collected at baseline and post-intervention.",[27],[435,484,485,486,487],"Cognitive reappraisal","Behavioral suppression","mindfulness","quality of life","2024-09-29",{"date":490,"type":46},"2024-10-02",{"date":492,"type":21},"2024-10",{"date":494,"type":21},"2024-11",{"name":496,"class":53},"Jordan University of Science and Technology",{"id":498,"slug":499,"hasResults":11,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":503,"eligibilityCriteria":504,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":505,"targetDuration":507,"studyType":356,"phases":4,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":159},"100521160","percutaneous-peritoneal-dialysis-catheter-insertion-predict-100521160","NCT06065982","Percutaneous Peritoneal Dialysis Catheter Insertion (PREDICT)","Prospective Observational Cohort Study on the Outcomes of Percutaneous Inserted PD Catheters","PREDICT","Inclusion Criteria:\n\n* Age \\> 18 years\n* Percutaneous PD catheter insertion between March 1st 2023 and March 1st 2026 Patients can be included 4 weeks before until 12 weeks after PD catheter insertion\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Life expectancy \\\u003C 3 months",{"count":506,"type":21},500,"1 Year","Peritoneal dialysis (PD) is the most frequent modality of home dialysis for patients with kidney failure.\n\nMost PD catheters are placed using a laparoscopic technique. This approach requires the availability of a qualified surgeon, time in the operating theater and general anaesthesia for the patient. Thus, the laparoscopic technique is less suitable for patients with severe heart failure or multimorbidity where general anaesthesia is not possible.\n\nPD catheters can also be inserted using a percutaneous strategy using a modified Seldinger technique. This strategy can be performed bedside under local anaesthesia, by the nephrologist, radiologist, a surgeon, physician assistant or qualified nurse.\n\nThe availability of the percutaneous implantation strategy of a PD catheter in a nephrology center may accomodate more patients to receive a PD catheter insertion, including those who have a contraindication to general anaesthesia or need urgent PD.\n\nThe PREDICT project aims to increase knowledge and competencies on percutaneous PD catheter insertions by training centers for this technique. By establisching a prospective registry, the outcomes of percutaneously inserted PD catheters, both in experienced and newly trained centers, will be assessed.",[331],"2023-09-29",{"date":512,"type":46},"2023-10-04",{"date":514,"type":46},"2023-06-23",{"date":516,"type":21},"2027-06-23",{"name":518,"class":53},"Universitair Ziekenhuis Brussel"]